

Doc set No.: UPVG0003-103  
API L. NO. 09/935,100

PATENT  
Filed: 08/22/2001

RECEIVED  
CENTRAL FAX CENTER

DEC 28 2006

**AMENDMENTS TO THE CLAIMS:**

Please amend claims 37 and add new claims 47-51.

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1-31. (Canceled)
32. (Previously presented) A pharmaceutical composition comprising
- a) anti-Vpr monoclonal antibodies; and
  - b) a pharmaceutically acceptable carrier.
33. (Previously presented) A method of treating an individual exposed to HIV by administering an effective amount of anti-Vpr antibodies.
34. (Previously presented) A method of treating an individual who has been infected with HIV comprising the step of administering to said individual a therapeutically effective amount of anti-Vpr antibodies.
35. (Canceled)
36. (Previously presented) The pharmaceutical composition of claim 32 wherein the anti-Vpr antibodies bind to a fragment of Vpr comprising amino acids 2-12.
37. (Currently amended) A pharmaceutical composition comprising:
- a) anti-Vpr antibodies that inactivate Vpr activity to reduce the rate of HIV viral production; inhibit Vpr enhancement of HIV replication; and

Doclet No.: UPVG0003-103  
APP. NO. 09/935,100

PATENT  
Filed: 08/22/2001

b) a pharmaceutically acceptable carrier;

wherein the anti-Vpr antibodies are present in an amount effective to reduce the rate of viral production ~~inhibit HIV replication~~ in an HIV infected individual.

38. (Previously presented) The pharmaceutical composition of claim 37 wherein the anti-Vpr antibodies are monoclonal antibodies.

39. (Canceled)

40. (Previously presented) The pharmaceutical composition of claim 37 wherein the composition is a sterile composition and the anti-Vpr antibodies bind to a fragment of Vpr comprising amino acids 2-12.

41. (Previously presented) The method of claim 33 wherein the anti-Vpr antibodies are monoclonal antibodies.

42. (Canceled)

43. (Previously presented) The method of claim 33 wherein the anti-Vpr antibodies bind to a fragment of Vpr comprising amino acids 2-12.

44. (Previously presented) The method of claim 34 wherein the anti-Vpr antibodies are monoclonal antibodies.

45. (Canceled)

46. (Previously presented) The method of claim 34 wherein the anti-Vpr antibodies bind to a fragment of Vpr comprising amino acids 2-12.

**Doc set No.: UPVC0003-103**  
**APL NO. 09/935,100**

**PATENT**  
**Filed: 08/22/2001**

47. (New) The pharmaceutical composition of claim 32 wherein the anti-Vpr antibodies are present in an amount effective to reduce the rate of viral production in an HIV infected individual.
48. (New) The method of claim 34 wherein the anti-Vpr antibodies inactivate Vpr activity to reduce the rate of HIV viral production.
49. (New) The method of claim 48 wherein the anti-Vpr antibodies are monoclonal antibodies.
50. (New) The method of claim 34 wherein the anti-Vpr antibodies inactivate Vpr activity to reduce the rate of HIV viral production.
51. (New) The method of claim 50 wherein the anti-Vpr antibodies are monoclonal antibodies.